(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The 10 Most Progressive Logical Disclosures - 2Iranian missile hit on Ne'ot Hovav factory leads to fear of chemical leakage
- 3Internet Bookkeeping Programming for Consultants
- 4Step by step instructions to Guarantee Your Fender bender Legal counselor has Areas of strength for a Record
- 5Step by step instructions to Appropriately Keep up with Your Sunlight powered chargers for Most extreme Productivity
- 8 Espresso Bean Starting points All over the Planet
- Manual for 6 Hot Brilliant Beds
- What’s your chronotype? Knowing whether you’re a night owl or an early bird could help you do better on tests and avoid scams
- Slovakia rejects EU call to scrap higher fuel prices for foreign cars
- Jamie Dimon warns Iran war could drive inflation, interest rates higher
- Proficient Cultivating Devices for a Lovely and Useful Nursery in 2024
- Latvia seeks emergency UN meeting over Russian missile attack on Lviv
- The best ice packs for coolers of 2026, tested and reviewed
- Doctor's orders? ‘Belly laugh at least two to five days a week'
